Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study

@inproceedings{Tanaka2010BiweeklyDC,
  title={Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study},
  author={Yoshihiro Tanaka and Kazuhiro Yoshida and Yuichi Sanada and Shinji Osada and Kazuya Yamaguchi and Takao Takahashi},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2010}
}
The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinoma. We studied a total of 18 patients who had previously… CONTINUE READING